Baxter blood filter shows potential benefit in severely ill COVID-19 patients

• Baxter International (BAX +1.8%) announces observational data from the OxirisNet Registry that support the rationale for using its Oxiris filter set for extracorporeal (outside of the body) blood purification (EBP) in severely ill COVID-19 patients.
• The results, recently published in the journal Critical Care, showed significant reductions in levels of interleukin-6 (IL-6), a pro-inflammatory protein, improvements in indicators of organ dysfunction and reductions in expected intensive care unit (ICU) mortality rate compared to historical control.
• The company says the 37-subject study was not designed to demonstrate a causal relationship between EBP treatment with Oxiris and these outcomes, but it does support the feasibility of its use with these patients.
• https://seekingalpha.com/news/3626439-baxter-blood-filter-shows-potential-benefit-in-severely-ill-covidminus-19-patients